Suppliers and packagers for AVERI

AVERI

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Avion Pharms	AVERI	desogestrel; ethinyl estradiol	TABLET;ORAL-21	218933	ANDA	Avion Pharmaceuticals, LLC	75854-604-01	1 BLISTER PACK in 1 CARTON (75854-604-01) / 1 KIT in 1 BLISTER PACK	2025-06-05
Avion Pharms	AVERI	desogestrel; ethinyl estradiol	TABLET;ORAL-21	218933	ANDA	Avion Pharmaceuticals, LLC	75854-604-03	3 BLISTER PACK in 1 CARTON (75854-604-03) / 1 KIT in 1 BLISTER PACK	2025-06-05
Avion Pharms	AVERI	desogestrel; ethinyl estradiol	TABLET;ORAL-28	218933	ANDA	Avion Pharmaceuticals, LLC	75854-604-01	1 BLISTER PACK in 1 CARTON (75854-604-01) / 1 KIT in 1 BLISTER PACK	2025-06-05

Averi Drug Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the supply chain for Averi, a pharmaceutical drug, focusing on key suppliers and their roles. The analysis identifies critical manufacturing partners and evaluates potential supply chain risks and opportunities.

What is Averi and its Therapeutic Area?

Averi is a novel therapeutic agent developed by [Developer Company Name, if known, otherwise state "a pharmaceutical company"]. Its primary indication is [Therapeutic Area, e.g., oncology, immunology, cardiovascular disease]. The drug targets [Mechanism of Action, if publicly available, e.g., a specific protein, pathway]. [Include any publicly available information on clinical trial status or market approval, e.g., "The drug is currently in Phase III clinical trials for [specific indication]," or "Averi received FDA approval on [Date] for the treatment of [Indication]."].

Who are the Primary Manufacturers of Averi?

The manufacturing of Averi, particularly its Active Pharmaceutical Ingredient (API) and finished drug product, involves specialized contract manufacturing organizations (CMOs). Identifying these partners is crucial for supply chain resilience and cost management.

Active Pharmaceutical Ingredient (API) Manufacturing:

The synthesis of the API for Averi is a complex multi-step process. Key suppliers in this domain are selected based on their expertise in [specific chemical synthesis techniques, e.g., chiral synthesis, peptide manufacturing] and their adherence to Good Manufacturing Practices (GMP).

• [Supplier Name 1]: This CMO is a primary manufacturer of Averi's API. They are located in [Country/Region]. Their capabilities include [mention specific capabilities, e.g., large-scale batch production, sterile API synthesis]. [Include any publicly available information on their facility size, capacity, or certifications relevant to Averi's production.] For instance, they operate a [number]-square-foot facility with [capacity metric, e.g., 10,000-liter reactor capacity]. [Cite Source].
• [Supplier Name 2, if applicable]: This supplier may serve as a secondary or back-up API manufacturer. Their role could be to provide [specific intermediates] or to handle overflow production. Their location is [Country/Region]. Capabilities include [mention specific capabilities]. [Cite Source].

Finished Drug Product (FDP) Manufacturing:

Once the API is synthesized and purified, it is formulated into the final dosage form of Averi (e.g., tablets, injectables). This step requires specialized facilities for formulation, filling, packaging, and labeling.

• [Supplier Name 3]: This CMO is responsible for the formulation and packaging of Averi into its final dosage form. They are based in [Country/Region]. Their expertise lies in [mention specific formulation types, e.g., sterile injectables, complex oral dosage forms]. Their facilities are equipped for [mention specific equipment or processes, e.g., aseptic filling, lyophilization, blistering]. [Include any publicly available information on their quality certifications or capacity, e.g., "The facility holds FDA and EMA approvals and can handle up to X million units annually."]. [Cite Source].
• [Supplier Name 4, if applicable]: Similar to API manufacturing, a secondary FDP manufacturer could be engaged to mitigate supply risks. This supplier might specialize in [specific dosage form or packaging] or operate in a different geographic region to ensure supply continuity. [Cite Source].

What are the Key Intermediates and Raw Materials for Averi?

The synthesis of Averi's API relies on a specific set of key intermediates and raw materials. The reliable sourcing of these components is fundamental to uninterrupted production.

Key Intermediates:

• [Intermediate A]: This is a critical precursor in the [early/mid/late] stages of Averi's API synthesis. Its availability and quality directly impact API yield and purity. Key suppliers for [Intermediate A] are often specialized chemical manufacturers. [If publicly known, mention geographical concentration of suppliers, e.g., "A significant portion of [Intermediate A] suppliers are located in Asia."] [Cite Source].
• [Intermediate B]: Another crucial building block, [Intermediate B], contributes [specific functional group or structural element] to the final API. Sourcing this intermediate requires suppliers with expertise in [specific chemical reactions]. [Cite Source].

Critical Raw Materials:

• [Raw Material X]: This is a fundamental chemical used in the initial reaction steps. Its purity is paramount. Suppliers typically possess large-scale chemical synthesis capabilities. [Cite Source].
• [Raw Material Y]: This solvent or reagent is essential for [specific process, e.g., purification, crystallization]. Availability of high-purity grades is a critical factor. [Cite Source].

What are the Geographic Concentrations and Risks in the Averi Supply Chain?

The geographic distribution of Averi's suppliers presents both strategic advantages and potential risks.

API Manufacturing:

• [Supplier Name 1] in [Country/Region]: The concentration of API manufacturing in [Country/Region] for Averi exposes the supply chain to [mention specific risks, e.g., geopolitical instability, trade disputes, natural disasters, regulatory changes]. For example, [cite a relevant past event or trend in that region impacting pharmaceutical supply chains, if available]. [Cite Source].
• [Supplier Name 2, if applicable] in [Country/Region]: If a secondary API supplier exists, its location in [Country/Region] may [either mitigate or exacerbate] the risks associated with the primary supplier.

Finished Drug Product (FDP) Manufacturing:

• [Supplier Name 3] in [Country/Region]: The FDP manufacturing in [Country/Region] is also a point of concentration. Risks in this region include [mention specific risks, e.g., labor shortages, increased logistics costs, import/export restrictions]. [Cite Source].

Intermediate and Raw Material Sourcing:

• Concentration in [Specific Region/Country]: If key intermediates or raw materials are predominantly sourced from a single region, such as [Region/Country], this creates a significant vulnerability. Disruptions in that region could halt the entire Averi production line. For example, recent global events have highlighted the fragility of supply chains for [mention a specific type of chemical or material] originating from [Region/Country]. [Cite Source].
• Single Source Dependencies: Reliance on a single supplier for a critical intermediate or raw material, regardless of geography, represents a high-risk scenario. [If specific single-source dependencies are known, list them. Otherwise, state the general risk].

What are the Patent Landscape and Exclusivity Periods for Averi?

Understanding the patent landscape is essential for forecasting market exclusivity and anticipating generic competition.

• Composition of Matter Patent: The foundational patent for Averi is [Patent Number, if known, or describe the patent type]. This patent grants exclusivity until [Expiration Date, approximate if exact is unavailable]. [Cite Source].
• Process Patents: Additional patents may cover specific manufacturing processes for the API or the drug product. These patents can extend market protection or create barriers for generic manufacturers. [If known, provide patent numbers and expiration dates for key process patents].
• Formulation Patents: Patents related to specific formulations or delivery systems can further enhance exclusivity. [If known, provide patent numbers and expiration dates].
• Regulatory Exclusivity: Beyond patent protection, regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity in the US or data exclusivity in Europe, provide additional periods of market protection. Averi may be eligible for [mention relevant regulatory exclusivity types and their typical durations]. For example, NCE exclusivity in the US is typically [number] years from approval. [Cite Source].

What are the Regulatory Considerations and Compliance Requirements for Averi Suppliers?

All suppliers involved in the Averi supply chain must adhere to stringent regulatory standards.

• Good Manufacturing Practices (GMP): Suppliers of both API and finished drug product must comply with cGMP regulations as enforced by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes robust quality management systems, validated manufacturing processes, and strict control over raw materials. [Cite relevant FDA or EMA guidance documents].
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines are critical for global pharmaceutical manufacturing. Key guidelines relevant to Averi suppliers include ICH Q7 (GMP for APIs) and ICH Q10 (Pharmaceutical Quality System). [Cite ICH guidelines].
• Environmental, Social, and Governance (ESG) Standards: Increasingly, pharmaceutical companies are scrutinizing the ESG practices of their suppliers. This includes environmental impact, labor practices, and ethical conduct. Suppliers may be required to demonstrate compliance with specific ESG frameworks. [Cite any known company policies or industry trends].
• Import/Export Regulations: Suppliers involved in international trade must navigate complex import and export regulations, including customs requirements, tariffs, and product registration.

Key Takeaways

• The Averi supply chain relies on specialized CMOs for both API and finished drug product manufacturing.
• Geographic concentration of key suppliers in [mention primary regions] presents potential risks related to geopolitical instability, natural disasters, and trade disputes.
• The patent landscape indicates market exclusivity until [latest known patent expiration date], with potential for extension through process and formulation patents.
• Adherence to GMP, ICH guidelines, and evolving ESG standards is a mandatory requirement for all Averi suppliers.
• Diversification of supplier base for critical intermediates and raw materials is essential to mitigate supply chain vulnerabilities.

Frequently Asked Questions

1. What is the primary therapeutic indication for Averi? Averi's primary indication is [Therapeutic Area, e.g., oncology, immunology, cardiovascular disease].

2. Which contract manufacturing organizations (CMOs) are involved in Averi's API production? Primary API manufacturing is conducted by [Supplier Name 1], with potential involvement from [Supplier Name 2, if applicable].

3. What is the anticipated expiration date for Averi's core patent protection? The composition of matter patent for Averi is expected to expire around [Expiration Date].

4. What are the main risks associated with the geographic concentration of Averi's manufacturing partners? Risks include geopolitical instability, trade disputes, natural disasters, and changes in regulatory environments within the concentrated regions.

5. Beyond patent exclusivity, what other forms of market protection does Averi have? Averi may benefit from regulatory exclusivities such as New Chemical Entity (NCE) exclusivity in the U.S. and data exclusivity in other major markets.

Citations

[1] [Full APA citation for Source 1, e.g., Company Press Release, Regulatory Filing, Industry Report, News Article with verifiable data] [2] [Full APA citation for Source 2] [3] [Full APA citation for Source 3] [4] [Full APA citation for Source 4] [5] [Full APA citation for Source 5] [6] [Full APA citation for Source 6] [7] [Full APA citation for Source 7] [8] [Full APA citation for Source 8] [9] [Full APA citation for Source 9] [10] [Full APA citation for Source 10]